Cargando…
Azithromycin for mild-to-moderate COVID-19
Autores principales: | Patel, Jigar, Berezowski, Ivan, Abdelmonem, Ahmed, Taylor, Dania, Pourmand, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428482/ https://www.ncbi.nlm.nih.gov/pubmed/34509194 http://dx.doi.org/10.1016/S2213-2600(21)00379-9 |
Ejemplares similares
-
High-dose budesonide for early COVID-19
por: Berezowski, Ivan, et al.
Publicado: (2021) -
Azithromycin for mild-to-moderate COVID-19 – Authors' reply
por: Hinks, Timothy S C
Publicado: (2021) -
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
por: Cavalcanti, Alexandre B., et al.
Publicado: (2020) -
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021) -
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
por: Lamback, Elisa Baranski, et al.
Publicado: (2021)